Patients?? subjective experiences on antipsychotic medications: implications for outcome and quality of life

1995 ◽  
Vol 10 (Supplement 3) ◽  
pp. 123-132 ◽  
Author(s):  
A G Awad ◽  
T P Hogan ◽  
L N P Vorugant ◽  
R J Heslegrave
Keyword(s):  
Quality Of Life ◽  
Subjective Experiences ◽  
Antipsychotic Medications

scholarly journals Tailoring interventions for social isolation among older persons during the COVID-19 pandemic: challenges and pathways to healthcare equity

2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Lise Dassieu ◽  
Nadia Sourial
Keyword(s):  
Quality Of Life ◽  
Older Adults ◽  
Social Isolation ◽  
Older Persons ◽  
Vulnerable Population ◽  
Subjective Experiences ◽  
Main Text ◽  
Healthcare Equity ◽  
Structural Inequities

Abstract Background Social isolation among older adults raises major issues for equity in healthcare in the context of the COVID-19 pandemic. Main text This commentary describes current challenges in preventing social isolation among older adults and proposes pathways to develop inclusive approaches to intervention in this vulnerable population. Building interventions that take account of structural inequities among older persons, as well as their subjective experiences, expectations and perspectives, appears fundamental to improve their health and quality of life in pandemic and post-pandemic contexts. Conclusions We argue that equity-based and person-centered approaches are critical to counter the negative outcomes of social isolation in the vulnerable older population.

scholarly journals Self-Assessment of Unilateral and Bimodal Cochlear Implant Experiences in Daily Life

2020 ◽  
Author(s):  
Elke M J Devocht ◽  
A. Miranda L Janssen ◽  
Josef Chalupper ◽  
Robert J Stokroos ◽  
Herman Kingma ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cochlear Implant ◽  
Daily Life ◽  
Subjective Experiences ◽  
Self Assessment ◽  
Hearing Ability ◽  
Hearing Handicap ◽  
General Quality ◽  
Contralateral Ear

AbstractObjectiveThe subjective experiences were assessed of cochlear implant (CI) users either wearing or not wearing a hearing aid (HA) at the contralateral ear.DesignUnilateral CI-recipients were asked to fill out a set of daily-life questionnaires on bimodal HA use, hearing disability, hearing handicap and general quality of life.Study sampleTwenty-six CI-recipients who regularly use a contralateral HA (bimodal group) and twenty-two CI-recipients who do not use a HA in the contralateral ear (unilateral group).ResultsComparisons between both groups (bimodal versus unilateral) showed no difference in self-rated disability, hearing handicap or general quality of life. However within the group of bimodal listeners, participants did report a significant benefit of bimodal hearing ability in various daily life listening situations.ConclusionsBimodal benefit in daily life can consistently be experienced and reported within the group of bimodal users.

Psylog, an EPA smartphone application to prevent antipsychotic side-effects

2014 ◽  
Vol 29 (S3) ◽  
pp. 672-673
Author(s):  
O. Andlauer ◽  
M. Rojnic-Kuzman
Keyword(s):  
Quality Of Life ◽  
Type 2 Diabetes ◽  
Side Effects ◽  
Psychiatric Care ◽  
Smartphone Application ◽  
Psychoeducational Intervention ◽  
Antipsychotic Medications ◽  
Antipsychotic Side Effects

Antipsychotic medications are used to treat a significant number of psychiatric disorders, such as schizophrenia or bipolar disorder, which have a significant impact on overall disability in Europe. Although these drugs have documented efficacy, they are also associated with side-effects such as drowsiness, weight gain, type 2 diabetes, or extrapyramidal symptoms [1]. These contribute to increasing overall morbidity and mortality [2], reduced quality of life, and can push patients to stop their medications. This often leads to relapse, and the need for a new hospital admission, which is detrimental to the patient, and create extra costs for the society. However, the monitoring of side-effects is rarely carried out in a standardized way in daily clinical practice. Smartphones are an acceptable and easy to use tool available to patients with schizophrenia [3]. The aim of the mPIVAS (mHealth psychoeducational intervention versus antipsychotic-induced side effects) project is to develop an effective and innovative smartphone application that can be used by psychiatrists and patients in order to monitor medications’ side-effects. The European Psychiatric Association (EPA) is involved in this project with the objective to develop this application in 6 languages. Part of the project includes training European early careers psychiatrists to the use Psylog and helping them to spread information about this new project in their own country, by organising local and national cascade courses. We expect an improvement in psychiatric care in all involved institutions through the education of employees, a better implication of patients in their disease, and an improved monitoring of antipsychotic side-effects.

Quality of life and functioning in first-episode psychosis Chinese patients with different antipsychotic medications

2015 ◽  
Vol 10 (6) ◽  
pp. 535-539 ◽  
Author(s):  
Edwin H.M. Lee ◽  
Christy L.M. Hui ◽  
Jessie J.X. Lin ◽  
Elaine Y.N. Ching ◽  
W.C. Chang ◽  
...  
Keyword(s):  
Quality Of Life ◽  
First Episode Psychosis ◽  
Chinese Patients ◽  
First Episode ◽  
Antipsychotic Medications ◽  
Episode Psychosis

scholarly journals Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations

2016 ◽  
Vol 18 (3) ◽  
pp. 323-337 ◽  
Keyword(s):  
Quality Of Life ◽  
Genetic Factors ◽  
Psychiatric Patients ◽  
Clinical Implications ◽  
Gene Variants ◽  
Clinical Tests ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Antipsychotic Medications ◽  
Factors Influencing

Optimizing antipsychotic pharmacotherapy is often challenging due to significant variability in effectiveness and tolerability. Genetic factors influencing pharmacokinetics and pharmacodynamics may contribute to some of this variability. Research studies have characterized these pharmacogenetic relationships, and some genetic markers are now available as clinical tests. These advances in pharmacogenetics research and test availability have great potential to improve clinical outcomes and quality of life in psychiatric patients. For clinicians considering using pharmacogenetics, it is important to understand the clinical implications and also the limitations of markers included in currently available tests. This review focuses on pharmacokinetic and pharmacodynamic gene variants that are currently available in commercial genetic testing panels. Associations of these variants with clinical efficacy and adverse effects, as well as other clinical implications, in antipsychotic pharmacotherapy are discussed.

scholarly journals Benefits of Switching from Typical to Atypical Antipsychotic Medications: A Longitudinal Study in a Community-Based Setting

2002 ◽  
Vol 47 (9) ◽  
pp. 870-874 ◽  
Author(s):  
Peter E Cook ◽  
Joel O Goldberg ◽  
Ryan J Van Lieshout
Keyword(s):  
Quality Of Life ◽  
Atypical Antipsychotic ◽  
Negative Symptoms ◽  
Mental Health Program ◽  
Community Support ◽  
Antipsychotic Medications ◽  
Crisis Services ◽  
Utilization Data ◽  
Atypical Antipsychotic Medications

Objective: This study examines the clinical and resource utilization effects of switching stable outpatients with schizophrenia from a typical to an atypical antipsychotic medication. Method: We monitored 43 schizophrenia patients from a community mental health program who tolerated switching from typical to atypical antipsychotic medications. We used the Positive and Negative Syndrome Scale (PANSS), Lehman Quality of Life Interview (QOL), and service utilization data for 2 years before and 2 years after the switch. Results: The switch to atypical antipsychotics was associated with significant improvements in positive symptoms, in general psychopathology, and in quality of life. Resource requirements, including case-management and crisis services and hospitalization days, were significantly reduced. We observed no changes in the sample's already low levels of negative symptoms. Conclusions: In stable outpatients with schizophrenia in a real-world setting, switching to an atypical antipsychotic can result in sustained, significant improvement in clinical response and quality of life, as well as in reduced need for hospitalization and community support,.

Sign in / Sign up

Export Citation Format

Share Document